Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Hepatol. Feb 27, 2023; 15(2): 303-310
Published online Feb 27, 2023. doi: 10.4254/wjh.v15.i2.303
Published online Feb 27, 2023. doi: 10.4254/wjh.v15.i2.303
Outcomes of gout in patients with cirrhosis: A national inpatient sample-based study
Ayham Khrais, Aaron Kahlam, Amjad Shaikh, Division of Medicine, Rutgers New Jersey Medical School, Newark, NJ 07103, United States
Ali Tahir, Division of Medicine, St. Luke’s University Health Network, Bethlehem, PA 18015, United States
Sushil Ahlawat, Division of Gastroenterology and Hepatology, Rutgers New Jersey Medical School, Newark, NJ 07103, United States
Author contributions: All authors contributed to the study conception and design; Khrais A contributed to material preparation, data collection and analysis and wrote the first draft of the manuscript; Kahlam A and Tahir A and all authors commented on previous versions of the manuscript; Ahlawat S revised the article critically for important intellectual content; All authors read and approved the final manuscript.
Institutional review board statement: This study utilized de-identified data from a public database and as such was exempt from institutional review.
Informed consent statement: Informed consent was not required.
Conflict-of-interest statement: All authors report no relevant conflicts of interest for this article.
Data sharing statement: Statistical code and database is available from the national inpatient sample at https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp. Consent was not obtained, but the presented data are anonymized, and risk of identification is non-existent as data were obtained from a public database.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ayham Khrais, DO, Staff Physician, Division of Medicine, Rutgers New Jersey Medical School, 150 Bergen Street, Newark, NJ 07103, United States. ak2017@njms.rutgers.edu
Received: October 7, 2022
Peer-review started: October 7, 2022
First decision: January 3, 2023
Revised: January 6, 2023
Accepted: February 10, 2023
Article in press: February 10, 2023
Published online: February 27, 2023
Peer-review started: October 7, 2022
First decision: January 3, 2023
Revised: January 6, 2023
Accepted: February 10, 2023
Article in press: February 10, 2023
Published online: February 27, 2023
Core Tip
Core Tip: Patients with cirrhosis had higher rates of gout-related complications including rates of flares. This could be due to the patients with cirrhosis having higher rates of hyperuricemia, predisposing them to worsening gout. Furthermore, patients with cirrhosis had lower rates of joint interventions, likely due to clinician hesitancy with performing such procedures due to an elevated risk of bleeding in patients with cirrhosis.